BioMedNewsBreaks Archive - Page 202 of 224

TuesdayNov 17, 2020 12:18 pm

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Q3 Numbers, Company Updates

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its financial results and provided business updates for the quarter ended Sept. 30, 2020. The report included a note that revenues of $0.5 million were level with the third quarter of last year, primarily driven through the sale of Predictive Oncology’s proprietary STREAMWAY product line. In addition, the company’s subsidiary, Soluble Biotech, moved into a new office and lab space and installed new equipment. POAI also signed its first contract with a pharmaceutical company for protein expression and solubility…

TuesdayNov 17, 2020 12:17 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Monday released a letter to stockholders from its CEO Dr. James Woody. The letter addresses the closing of the merger with KBLM Merger Corp IV, which resulted in 180 Life Sciences now operating as a stand-alone publicly traded company with its common stock listed on the Nasdaq Capital Market under the symbol “ATNF.” In the update, Dr. Woody shares a little about himself and the…

TuesdayNov 17, 2020 11:13 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Files IND Application for Berubicin in Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for Berubicin in the treatment of Glioblastoma Multiforme (“GBM”). Pending the FDA's acceptance of the company's filing, CNS Pharmaceuticals plans to evaluate the efficacy of Berubicin in a Phase 2 Trial for adults with GBM who have failed first-line therapy and commence the trial within the first quarter of 2021. “Our laser focus from…

MondayNov 16, 2020 2:19 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation Schedule for Upcoming Investor Conferences

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will participate in two upcoming investor conferences. According to the update, Processa will participate in one-on-one meetings at the Craig-Hallum Alpha Select Virtual Conference on Tuesday, Nov. 17, 2020, and the Benchmark Annual Discovery 1x1 Investor Virtual Conference on Wednesday, Nov. 18, 2020. Interested parties should contact their conference representative or James@HaydenIR.com to schedule a one-on-one meeting with management. To view the full press release, visit https://ibn.fm/biHn2 About Processa Pharmaceuticals Inc.…

MondayNov 16, 2020 10:48 am

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Annual General Shareholder’s Meeting Results, Secures Order for MiQLab(TM) System

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, on Friday announced the voting results of the company’s 2020 Annual General Shareholder’s Meeting held on November 10, 2020 in Vancouver, British Columbia. According to the update, a total of 48,273,080 common shares were voted at the meeting, representing 42.26% of the votes attached to all outstanding common shares of the company. All matters presented for shareholder approval at the meeting were duly authorized and approved. In addition, LexaGene today announced its receipt of a purchase order for a MiQLab(TM) system from…

FridayNov 13, 2020 11:29 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q3 2020 Results, Provides Corporate Update

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products intended to provide treatment for and improve the survival and/or quality of life for patients with unmet medical needs or no alternative treatment, on Thursday released its financial results for the third quarter of 2020. In addition, Processa provided a business update via conference call, for which the replay may be accessed at https://ibn.fm/BdxSB or by dialing 877-481-4010 (Toll-free) or 919-882-2331 (International) and entering replay passcode: 38528. “The third quarter was a period of tremendous value creation. Over that time, we in-licensed important clinical drug…

FridayNov 13, 2020 10:31 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today reported its financial results for the fiscal 2021 second quarter ended September 30, 2020. In addition, the company provided an update on its CNS pipeline and business progress. “We see a significant rise in mental health concerns as the global COVID-19 pandemic continues to impact the daily lives of millions of individuals. We are committed to developing innovative therapies that provide relief to those suffering from anxiety and depression, and we are working diligently towards that goal,” said VistaGen…

ThursdayNov 12, 2020 3:31 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Poised at Convergence of AI, Cancer Care

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company, focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid in clinical decision-making and lead to better health outcomes. A recent article discussing growing opportunity in this sector reads, “The National Cancer Institute (‘NCI’) in the United States has separately revealed that it is increasingly looking to invest in supporting research and developing infrastructure centered around the usage of…

ThursdayNov 12, 2020 1:15 pm

BioMedNewsBreaks – CB Scientific Inc. (CBSC) Enters Definitive Agreement to Acquire Datrix LLC

CB Scientific (OTC: CBSC), engaged in providing innovative products and services for the ambulatory noninvasive cardiac monitoring space, today announced definitive purchase agreement to acquire Datrix LLC, a global ambulatory device manufacturer based in Escondido, California. Datrix brings to CBSC a diversely experienced team of highly qualified individuals with extensive knowledge of design and engineering related to medical devices utilized in this ever-expanding market. The acquisition further strengthens CBSC’s digital offering with the addition of an existing commercially available product line, which includes wireless mobile cardiac telemetry, cardiac event, extended and standard holter monitoring through the Datrix Sirona and VX3…

ThursdayNov 12, 2020 12:03 pm

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Reports Positive Preclinical Data on PH94B’s Mechanism of Action

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced new in vitro electrophysiology data. According to the update, the data demonstrate that the mechanism of action of PH94B, the intranasal neuroactive steroid the company is preparing for Phase 3 development as a potential acute rapid-onset treatment of anxiety in adults with social anxiety disorder, does not involve direct activation of GABA-A receptors, in distinct contrast to the mechanism of action of benzodiazepines (“benzos”), which act as direct positive modulators of GABA-A receptors. “We are very pleased with…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Q3 Numbers, Company Updates

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Files IND Application for Berubicin in Treatment of GBM

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation Schedule for Upcoming Investor Conferences

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Annual General Shareholder’s Meeting Results, Secures Order for MiQLab(TM) System

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q3 2020 Results, Provides Corporate Update

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Poised at Convergence of AI, Cancer Care

BioMedNewsBreaks – CB Scientific Inc. (CBSC) Enters Definitive Agreement to Acquire Datrix LLC

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Reports Positive Preclinical Data on PH94B’s Mechanism of Action

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search